ARCALYST ® (rilonacept) is an interleukin-1 blocker indicated for: Treatment of Recurrent Pericarditis (RP) and reduction in risk of recurrence in adults and pediatric patients 12 years and older. Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS), and Muckle-Wells Syndrome ...

Rilonacept, sold under the brand name Arcalyst, is a medication used to treat cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome, and Muckle–Wells syndrome; deficiency of interleukin-1 receptor antagonist; and recurrent pericarditis.

FDA has approved Arcalyst (rilonacept) injection to treat recurrent pericarditis and reduce the risk of recurrence in adults and children 12 years and older. Recurrent pericarditis is...

2024年5月1日 · Arcalyst (rilonacept) is used to treat Cryopyrin-Associated Periodic Syndromes, Deficiency of Interleukin-1 Receptor Antagonist, and recurrent pericarditis. Includes Arcalyst side effects, interactions and indications.

ARCALYST™ (rilonacept) is an interleukin-1 blocker indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and...

ARCALYST is a patient-administered, once-weekly, subcutaneous injection for recurrent pericarditis. Learn about dosing options for adults and adolescents.

2021年3月20日 · 近日，该公司宣布，美国食品和药物管理局（FDA）已批准Arcalyst（rilonacept），用于年龄≥12岁的儿童和成人，治疗复发性心包炎、降低复发风险 ...

2025年3月7日 · ARCALYST is a prescription medicine called an interleukin-1 (IL-1) blocker. ARCALYST is used to treat adults and children 12 years and older with Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS), and Muckle-Wells Syndrome (MWS)

2021年03月18日，Kiniksa Pharmaceuticals宣布，美国FDA已批准该公司开发的IL-1抑制剂Arcalyst（rilonacept）上市，用于治疗12岁以上复发性心包炎（recurrent pericarditis）患者和减轻心包炎的复发风险。

ARCALYST is the first and only FDA-approved treatment for recurrent pericarditis in people 12 years and older. It’s also proven to prevent future flares. WHY ARCALYST? 2 of 30 participants taking ARCALYST had a flare. In both cases, the flare happened during a temporary interruption (1 to 3 weekly doses) in ARCALYST treatment.